marked.bio

Company

Qilu Pharmaceutical

7 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

iparomlimab and tuvonralimab 3QLS31905 3

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

7 of 18 trials shown

  1. A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

    Recruiting Phase 3 Qilu Pharmaceutical Started 2024Primary completion 2030-12 NCT06686576

    iparomlimab and tuvonralimabcapecitabine

    Has a tumor demonstrating the presence of MSI-H/ dMMR

    MSI-H / dMMRColon Cancer

  2. A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Not yet recruiting Phase 1/2 Qilu Pharmaceutical Started 2025Primary completion 2026-09 NCT06949761

    QLC1101+QL1203QLC1101+QL2107iparomlimab and tuvonralimabdocetaxel

    Subjects confirmed advanced (metastatic or unresectable) solid tumors with KRAS G12D mutations.

    KRAS G12DSolid Tumor

  3. Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

    Not yet recruiting Phase 2 Qilu Pharmaceutical Started 2025Primary completion 2026-10 NCT07151872

    QLS31905gemcitabinecisplatinQL2107 Injectionoxaliplatincapecitabine

    Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

    Claudin 18.2 expressionCLDN18.2-positive Advanced Biliary Tract Cancer

  4. Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    Not yet recruiting Phase 2 Qilu Pharmaceutical Started 2025Primary completion 2026-12 NCT06942767

    QLS31905QL2107 Injectionoxaliplatincapecitabine

    Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction…

    Claudin 18.2 expressionGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  5. Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

    Not yet recruiting Phase 2 Qilu Pharmaceutical Started 2024Primary completion 2026-06 NCT06446388

    QLS31905oxaliplatincapecitabinegemcitabinecisplatiniparomlimab and tuvonralimabChemotherapy drug

    Tumor tissue samples determined to be positive for Claudin18.2 by immunohistochemistry (IHC);

    Claudin 18.2 expressionStatus may be outdated, last updated 2024-06-06Advanced Solid Tumor

  6. This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.

    Not yet recruiting Phase 1 Qilu Pharmaceutical Started 2026Primary completion 2028-06 NCT07552376

    QLS1317

    Participants with advanced solid tumors of MSI-H/dMMR who have failed standard treatment.

    MSI-H / dMMRMSI-H or dMMR Advanced Solid Tumors

  7. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Qilu Pharmaceutical Started 2024Primary completion 2026-05 NCT06403735

    QLC1101

    …h histologically confirmed advanced (metastatic or unresectable) solid tumors harboring a KRAS G12D mutation.

    KRAS G12DStatus may be outdated, last updated 2024-05-08Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor